Trinity Biotech plc (NASDAQ:TRIB – Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 29,100 shares, a decline of 50.3% from the December 15th total of 58,500 shares. Based on an average daily trading volume, of 207,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the shares of the company are sold short.
Trinity Biotech Stock Performance
NASDAQ TRIB traded up $0.03 on Wednesday, reaching $0.80. The stock had a trading volume of 92,435 shares, compared to its average volume of 262,025. The stock has a market cap of $6.08 million, a P/E ratio of -0.35 and a beta of 1.01. The business’s 50-day moving average price is $1.04 and its 200 day moving average price is $1.72. Trinity Biotech has a 12-month low of $0.75 and a 12-month high of $3.55.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC raised its holdings in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned about 4.72% of Trinity Biotech worth $390,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 78.97% of the company’s stock.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Further Reading
- Five stocks we like better than Trinity Biotech
- The 3 Best Blue-Chip Stocks to Buy Now
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- How Do Stock Buybacks Affect Shareholders?
- Stock Sentiment Analysis: How it Works
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
